Changes / RenewalRSSAbout RSS
- Aug 27, 2018 Release JT Signs a Letter of Intent to Initiate Discussion to Terminate Agreements on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan（PDF）
- July 30, 2018 Information " Financial Results " was updated.
- July 23, 2018 Information " Annual Report " was updated.
- June 28, 2018 Release JT and Torii Discontinue Development of NK-1 Receptor Antagonist (JTS-661) and Terminate Exclusive License Agreement with Menlo Therapeutics（PDF）
- May 24, 2018 Release Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis（PDF）